StockData
Maravai LifeSciences Holdings, Inc. logo

Maravai LifeSciences Holdings, Inc. (MRVI) stock

MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)

Close on Nov 17, 2026Market cap $1.89BP/E –Yield –

Earnings

Maravai LifeSciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 5, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$51.40M
+8.4% on a year earlier
Adjusted fully diluted loss per share (non-GAAP), Q2 FY2026
-$0.02
-$0.08 a year earlier
Latest guidance
Raised
Aug 6, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Maravai LifeSciences's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 30, 2026Nov 5, 2026Expected–––––
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$51.40M+8.4%-$0.08-$0.02Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$65.80M+40.3%-$0.02$0.01Release
Q4 FY2025ended Dec 31, 2025Feb 25, 2026after the close$49.90M–-$0.24-$0.04Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025after the close$41.60M-36.2%-$0.18-$0.08Release
Q2 FY2025ended Jun 30, 2025Aug 11, 2025after the close$47.40M-35.4%-$0.27-$0.08Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close$46.90M-26.9%-$0.21-$0.08Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025after the close––––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$65.20M-2.5%-$0.70-$0.02Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$73.40M+6.5%-$0.05$0.00Release
Q1 FY2024ended Mar 31, 2024May 8, 2024after the close$64.20M-18.7%-$0.09-$0.02Release
Q4 FY2023ended Dec 31, 2023Feb 22, 2024after the close$74.10M-63.8%-$0.80$0.01Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Maravai LifeSciences's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2026$205.00M – $215.00M$205.00M – $215.00MReaffirmedAug 6, 2026
Adjusted EBITDA (non-GAAP)non-GAAPFY2026$33.00M – $35.00M$30.00M – $32.00MRaisedAug 6, 2026

Guidance vs results

The last range Maravai LifeSciences gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$185.00M$185.80MΣ4QAbove range

Guidance history

Every forecast Maravai LifeSciences put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 6, 2026Adjusted EBITDA (non-GAAP)FY2026$33.00M – $35.00MRaised
Aug 6, 2026RevenueFY2026$205.00M – $215.00MReaffirmed
May 7, 2026Adjusted EBITDA (non-GAAP)FY2026$30.00M – $32.00MRaised
May 7, 2026RevenueFY2026$205.00M – $215.00MRaised
Feb 25, 2026Adjusted EBITDA (non-GAAP)FY2026$18.00M – $20.00MNew
Feb 25, 2026RevenueFY2026$200.00M – $210.00MNew
Nov 6, 2025RevenueFY2025$185.00MNew
May 12, 2025RevenueFY2025$185.00M – $205.00MNew
Feb 25, 2025revenueFY2024$255.00M – $265.00MReaffirmed
Nov 7, 2024Adjusted EBITDA (non-GAAP) marginsFY202416% – 18%Lowered
Nov 7, 2024revenueFY2024$255.00M – $265.00MLowered
Aug 7, 2024Adjusted EBITDA (non-GAAP) marginsFY202420% – 22%Lowered
Aug 7, 2024RevenueFY2024$265.00M – $285.00MReaffirmed
May 8, 2024Adjusted EBITDA (non-GAAP) marginsFY202423% – 25%New
May 8, 2024Revenue expectationsFY2024$265.00M – $285.00MReaffirmed
Feb 22, 2024Adjusted EBITDA (non-GAAP) marginsFY202423% – 25%New
Feb 22, 2024RevenueFY2024$265.00M – $285.00MNew
Nov 7, 2023Adjusted EBITDAFY2023$55.00M – $60.00MLowered
Nov 7, 2023Adjusted fully diluted EPSFY2023-$0.01 – $0.01Lowered
Nov 7, 2023interest expenseFY2023$16.00M – $18.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Maravai LifeSciences filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Results
  4. Results
  5. Results
  6. Results
  7. Update
  8. Update
  9. Results
  10. Results
  11. Results
  12. Results
  13. Update
  14. Results
  15. Results

See a number that looks wrong?